Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


People In Brief

This article was originally published in The Tan Sheet

Executive Summary

Winckler heads FDLI: The Food and Drug Law Institute names Susan Winckler, a former FDA chief of staff, as its president and CEO. Effective Nov. 6, Winckler replaced James Kelly, who announced his departure at the end of the summer. Winckler, a pharmacist and attorney who also has been VP of policy and communications and staff counsel for the American Pharmacists Association, joined FDA as director for policy communications in September 2006 under former Commissioner Andrew von Eschenbach, coordinating staff activities in the Office of the Commissioner and serving as the principal liaison to the Department of Health and Human Services. In January 2007 she took on a stronger formal role in FDA's newly created Office of the Chief of Staff, where she served as the main point of contact between the agency's centers and offices and the commissioner. Winckler left FDA in June after Commissioner Margaret Hamburg began appointing her own executive staff (1"The Tan Sheet" July 27, 2009)

You may also be interested in...

Commissioner Hamburg: Moving FDA Beyond A Regulatory Agency

Of the leading candidates for FDA commissioner in the Obama administration, Margaret Hamburg seemed among those with the least relevant experience -- an illustrious career to be sure, but one that lacked a decision-making role involving medical products

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

People In Brief

Perrigo promotes in pricing, planning





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts